Pharma Penny Stock Jumps 6.69% On New Order Win, Shares Rally 292% In 2-Yrs

Small cap stock operating under the pharmaceuticals sector, Veerhealth Care Limited shares today zoomed 6.69% to settle at Rs 23.92 per share on BSE. The company today bagged an order from its existing US client which led to rally in its shares. Veerhealth Care shares offered attractive returns of 292% in last 2-years and soared over 13% in last 3-months. The company's market capitalisation stood at Rs 47.84 crore. Check details below:

Veerhealth Care Bags New Order: As per the BSE filing of pharma company dated September 12, 2024, "Veerhealth Care Limited is proud to announce, that the Company has received further Export Order worth US$ 40111 (~ 33.35 Lakhs Approx.) from existing top institutional supplier Company in United States of America. Out of the total orders received till date of US$ 521525.12 (~ 433 Lakhs Approx.), Company has successfully manufactured and shipped orders worth US$ 350000 (~ 294 Lakhs Approx.) and balance orders are expected to be shipped by 30.10.2024."

Veerhealth Care Shares Performance: The 52-week high price of Veerhealth Care share on BSE is Rs 30.10 per share (as on 23/02/2024) and 52-week low price is Rs 13.60 per share (as on 13/12/2023), respectively. Veerhealth Care shares offered return of 17% in last 6-months, surged 16% in last 1-year, and rallied 372% in last 3-years. In last 5-years, Veerhealth Care shares gained 491% and 73% in last 10-years.

Veerhealth Care Bonus Share: It recommended bonus share in 2023 in the proportion of 1:1 and shares traded ex-bonus in September 22, 2024.

Veerhealth Care About: It came into existence in 1992 and operates in pharmaceuticals sector. VeerHealth Care Ltd. is a company that manufactures and supplies personal care, oral care, and Ayurvedic medicines. It is also engaged in the manufacturing of oral care products.

Disclaimer:

The stock just highlights the order win and is not a recommendation to buy, sell or hold. We have not done fundamental or technical analysis and have no opinion on the stock mentioned. Neither, the author nor Greynium Information Technologies should be held liable for any losses. Please consult a professional advisor.